MicroConstants Welcomes Pat deLisio as Director of East Coast Business Development

SAN DIEGO, CA, April 2, 2013 – MicroConstants, a regulated bioanalysis and DMPK specialty Contract Research Organization (CRO) in San Diego, California, announces the appointment of Patricia deLisio as their new director of east coast business development. Pat joins MicroConstants’ business development team with more than 12 years of experience selling contract research services to companies in the pharmaceutical, biotech, agrochemical, animal health, and specialty chemical industries. As the director of east coast business development, Pat will be responsible for developing new business opportunities in the region and implementing innovative sales and marketing strategies to help further the company’s mission of becoming the recognized leader in bioanalytical and pharmacokinetic analysis.

Prior to joining MicroConstants, Pat held business development and program management positions at several bioanalytical and toxicology CROs throughout the United States. She also spent more than three years as an independent GLP quality assurance consultant. Pat began her career as a research chemist, has spent 11 years as a study director/principal investigator, and has extensive experience in HPLC method development and validation for sample analysis supporting regulated toxicology and metabolism studies. Pat received her bachelor’s degree in Chemistry from Notre Dame College in South Euclid, Ohio.

“Pat’s extensive knowledge of the pharmaceutical development process and her experience establishing and securing new customer opportunities will be a tremendous asset to MicroConstants’ business development team as we focus on enhancing our presence in key geographic regions on the east coast,” says Gilbert Lam, president and chief scientific officer at MicroConstants. “This new role will also allow us to provide additional resources to our clients throughout the United States.”

About MicroConstants, Inc.
MicroConstants is a GLP-compliant Contract Research Organization (CRO) focused on performing regulated bioanalysisdrug metabolism and pharmacokinetic analysis to support discovery, preclinical and clinical drug development studies. They specialize in method development, method validation and sample analysis of small molecules, proteins, peptides and metabolites using LC/MS/MS, HPLC/UV, and immunoassay techniques. For more information, please visit www.microconstants.com.

For more information, contact:

MicroConstants, Inc.
+1 (858) 652-4600